Navigation Links
Codexis Achieves Development Milestones With Teva
Date:5/16/2011

REDWOOD CITY, Calif., May 16, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced the continued expansion of its collaboration with Teva Pharmaceutical Industries Ltd., the world's largest generic drug manufacturer.  Codexis has now successfully completed technology transfer of custom biocatalysts for manufacture of three undisclosed pharmaceutical products to Teva.  Two products have been transferred to pilot manufacturing and a third to full scale commercial manufacturing.  The original agreements covering development of these processes were signed in 2009.  

Teva is using Codexis biocatalysis technology to reengineer key process steps in the manufacture of the covered generic products.  Codexis develops proprietary custom biocatalysts which can reduce pharmaceutical manufacturing development time and costs.  Codexis technology is used by leading drug and chemical companies worldwide.  Financial terms were not disclosed.

"These are significant achievements in our relationship with Teva," said Joseph Sarret, M.D., Senior Vice President and Chief Business Officer.  "We are developing custom biocatalytic manufacturing processes for four Teva products, and the transfer to pilot and commercial manufacturing is important recognition of the cost savings and value-added technology that Codexis brings to the highly competitive generics marketplace."

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis’ technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture. Other potential markets for the company’s biocatalyst-enabled solutions include chemicals and water treatment.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis development of biocatalysts for use in creating manufacturing processes for certain Teva products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis Quarterly Report on Form 10-Q dated May 6, 2011 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

www.codexis.com

Contacts: 

Media: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  

Investors:  Henk Adriaenssens, ir@codexis.com, 650-421-8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Codexis Expands Pharmaceutical Manufacturing Partnerships
5. Codexis, Inc. Announces Pricing of Initial Public Offering
6. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
7. Codexis Names Peter Strumph SVP, Commercial Operations
8. Codexis to Present at the Pacific Crest Technology Leadership Forum
9. Codexis Expands Codex® Panel Product Family at CPhI
10. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
11. Codexis to Present at Piper Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):